Industry context
Capricor Therapeutics Inc [CAPR]
Last Updated 23 Jun 2026 @ 16:00 (Exchange is closed)
Last: $29.60
0.89%
1.43 (↓)
GaG Algo Score™
v1.0
Short
1.43 (↓)
Medium
2.50 (↓)
Long
3.06 (↓)
BUY
71.43%
return 34.82%
SELL
68.00%
return 39.73%
Line
Pivot Data
Pivot Statistics
| Metric | Average | Median | Std Dev |
|---|---|---|---|
| Gain % | 107.92% | 44.66% | 161.59% |
| Loss % | -34.58% | -35.38% | 12.18% |
| Duration | 27.4d | 22d | 16.2d |
| Total Pivots Found | 30 |
| Gain/Loss Legs | 29 (15 Gain / 14 Loss) |
| Last Pivot | Top @ $35.34 on 2026-04-21 |
| Change since Last Pivot | $-5.74 (-16.24%) |
Next Pivot Prediction Last: $29.60
| Predicted Next Type | Bottom |
| Predicted Price (Avg) | $23.12 |
| Predicted Price (Median) | $22.84 |
| Predicted Price Range (~68%) | $18.82 - $27.42 |
| Change to Avg Target | $-6.48 (-21.89%) |
| Predicted Date (Avg) | 2026-05-18 |
| Predicted Date Range (~68%) | 2026-05-02 - 2026-06-03 |
| Basis | Based on 14 historical losses (Avg: -34.58%, Median: -35.38%, StdDev of Abs: 12.18%) and duration (Avg: 27.4 days, StdDev: 16.2 days) |
| Note | Ranges assume ~normal distribution & historical patterns repeat. Use with caution. |
Modest rise for Capricor Therapeutics Inc.
Capricor Therapeutics Inc (CAPR) stock price showed improvement on Tuesday after the stock rose $0.260 (0.89%) from the previous session on below-average volume. Showing significant relative strength, the stock rose today while the NASDAQ fell -2.21%.(The stock has risen 3 days straight. This extended rally increases the chances of a price pullback soon) Yesterday's trading volume was 794 685 shares, worth about $23.52M. This represents 963 915 shares less than the day before. Volume was below the 10-day average of 1.31M shares.
Capricor Therapeutics Inc signals
There is no conclusive signals given from RSI. The price is above both moving averages, but the short-term average remains below the long-term average; upward momentum is present but not yet fully confirmed. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (20%), medium- (20%), and long-term (20%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Capricor Therapeutics Inc Support & Resistance Levels
The stock is approaching the closest resistance level at $30.00. approximately $0.400 (1.35%) away. Approaching it. Breaking above this level could signal further upside where next resistance level will be found at $30.4. On a fall back there will be support at $10.3 The dis das resistance s110.3 -
Capricor Therapeutics Inc Evaluation
- Short score: 1.43
- Medium score: 2.50
- Long score: 3.06
Ownership flow
GetAGraph InsiderPower
Transactions
71
Buy power
3 886 278
Sell power
330 093
2026-05-26
Maurer Michael T
Buy
2026-05-26
Maurer Michael T
Unknown
2026-05-25
Maurer Michael T
Buy
2026-05-25
Maurer Michael T
Buy
2026-05-18
Bergmann Anthony
Sell
Relationship map
Correlation snapshot
<span style="background-color: lightcoral">Overvalued: <i class="arrow arrow-down"></i>0.92% <strong>$29.88</strong> paired level.</span>
Positioning pressure
Short interest pressure
Short interest
24.21%
Of outstanding shares
Short float
27.11%
Of tradable float
Days to cover
14.28
Short interest divided by average volume
Squeeze probability
98.20%
+1.40% change
Short positioning is elevated and could amplify sharp price moves.
Updated 2026-05-29Earnings quality
Earnings history
Reported quarters
10
EPS beats
5
EPS misses
5
Avg. surprise
-29.26%
| Period | Date | Actual EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|---|
| Q3/2025 | 2025-11-11 | - | - | - | - |
| Q2/2025 | 2025-08-06 | - | $-0.430 | - | - |
| Q1/2025 | 2025-05-13 | $-0.530 | $-0.330 | -60.61% | - |
| Q4/2024 | 2025-03-19 | $-0.160 | $-0.310 | 48.39% | 11.13M |
| Q3/2024 | 2024-11-13 | $-0.380 | $-0.340 | -11.76% | 2.26M |
| Q2/2024 | 2024-08-07 | $-0.350 | $-0.320 | -9.37% | 3.97M |
| Q1/2024 | 2024-05-13 | $-0.310 | $-0.110 | -181.82% | 4.91M |
| Q4/2023 | 2024-02-29 | $-0.0200 | $-0.230 | 91.30% | 12.09M |
Analyst view
Analyst targets
Consensus
$50.00
Median
$50.00
Low
$38.00
High
$62.00
News flow
Latest company news
Market coverage
newsfilecorp.com Caprock Announces Closing of Private Placement Jun 19, 2026 newsfilecorp.com Early Warning Press Release - Frank Guillemette Announces Completion of Acquisition of Common Shares of Caprock Mining Corp. Jun 17, 2026 newsfilecorp.com Caprock Announces Proposed Private Placement Jun 12, 2026 newsfilecorp.com Caprock Announces Consistent High-Grade Intercepts from the Final Three Deep Drill Holes at Destiny, Including 8.32 g/t Au over 2.6m Jun 12, 2026Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Currency
USD
Capricor Therapeutics Inc is a clinicalstage biotechnology company focused on pioneering transformative cell and exosomebased therapies to treat and prevent a diverse range of diseases and disorders Their lead therapeutic CAP1002 is an allogeneic cell therapy derived from heart tissue This candidate has successfully completed its Phase III clinical trial for patients afflicted with latestage Duchenne muscular dystrophy DMD CAP1002 is simultaneously progressing through Phase II clinical testing to address cytokine storm associated with SARSCoV2 Beyond CAP1002 the company is advancing CAP2003 through preclinical development aiming to treat traumarelated injuries and medical conditions Furthermore Capricor is developing two vaccine candidates with the potential to prevent COVID19 Capricor collaborates with Lonza Houston Inc for the clinical manufacturing of CAP1002 supporting its use in DMD and other indications The company was established in 2005 and is headquartered in San Diego California
Navigation